Halazepam is a benzodiazepine derivative and is marketed under the brand names Alapryl and Pacinone It is no longer marketed in the United States. It had been marketed under the name Paxipam, but was withdrawn by its manufacturer, Schering Plough, for poor sales. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. It is a trifluoroethyl derivative of nordazepam. While its structure may be similar to chlordiazepoxide and diazepam, it has both less toxicity and less tendency to cause paradoxical hostility and aggression than either of them. Halazepam has active benzodiazepine metabolites.
^Greenblatt, D. J.; A. Locniskar and R. I. Shader (June 12, 1982). "Halazepam, another precursor of desmethyldiazepam". Lancet1 (8285): 1358–9. PMID6123659.Cite uses deprecated parameters (help)
^Fann, W. E.; W. M. Pitts and J. C. Wheless (Mar–Apr 1982). "Pharmacology, efficacy, and adverse effects of halazepam, a new benzodiazepine". Pharmacotherapy2 (2): 72–9. PMID6152591.Cite uses deprecated parameters (help)
^Jochemsen R, Breimer DD (1984). "Pharmacokinetics of benzodiazepines: metabolic pathways and plasma level profiles". Curr Med Res Opin. 8. Suppl 4: 60–79. PMID6144464.
^Lozano, Lozano, Lozano, et al. (1990). "[Open clinical study of the efficacy and safety of Halazepam in anxiety disorders]". Actas Luso Esp Neurol Psiquiatr Cienc Afines (in Spanish; Castilian) 18 (4): 205–11. PMID1981637.